A Randomized, Phase 2 Study of the Efficacy and Tolerability of Veliparib in Combination With Temozolomide or Veliparib in Combination With Carboplatin and Paclitaxel Versus Placebo Plus Carboplatin and Paclitaxel in Subjects With BRCA1 or BRCA2 Mutation and Metastatic Breast Cancer

Trial Profile

A Randomized, Phase 2 Study of the Efficacy and Tolerability of Veliparib in Combination With Temozolomide or Veliparib in Combination With Carboplatin and Paclitaxel Versus Placebo Plus Carboplatin and Paclitaxel in Subjects With BRCA1 or BRCA2 Mutation and Metastatic Breast Cancer

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 26 Jul 2018

At a glance

  • Drugs Veliparib (Primary) ; Carboplatin; Paclitaxel; Temozolomide
  • Indications Advanced breast cancer
  • Focus Therapeutic Use
  • Acronyms BROCADE
  • Sponsors Abbott Laboratories; AbbVie
  • Most Recent Events

    • 30 May 2018 Planned End Date changed from 10 Aug 2018 to 30 Nov 2018.
    • 30 May 2018 Planned primary completion date changed from 10 Aug 2018 to 30 Nov 2018.
    • 12 Feb 2018 Planned End Date changed from 15 Dec 2017 to 10 Aug 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top